{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:10:20Z","timestamp":1759032620146,"version":"3.37.3"},"reference-count":11,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2019,12,11]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>COPD and asthma prevalence is associated with socioeconomic status (or \u201cdeprivation\u201d), yet deprivation is rarely considered in typical large-scale efficacy randomised controlled trials that recruit highly selected patient populations. In this<jats:italic>post hoc<\/jats:italic>analysis of the Salford Lung Studies in COPD and asthma (two 12-month, open-label, effectiveness randomised controlled trials conducted in UK primary care), we evaluated the impact of patient deprivation on clinical outcomes with initiating fluticasone furoate\/vilanterol<jats:italic>versus<\/jats:italic>continuing usual care.<\/jats:p><jats:p>Patients were categorised into deprivation quintiles based on postcode and a countrywide database of indices of deprivation, and trial outcomes by quintile were assessed.<\/jats:p><jats:p>52% of patients in the COPD study were included in the most deprived quintile, contrasting with 20% in the asthma study. Greater deprivation was associated with higher rates of primary\/secondary healthcare contacts and costs. However, the treatment effect of fluticasone furoate\/vilanterol<jats:italic>versus<\/jats:italic>usual care for primary (COPD: moderate\/severe exacerbations; asthma: Asthma Control Test responders at week 24) and secondary\/other (healthcare consumption, adherence, treatment modifications, study withdrawals, exacerbations, serious adverse events) outcomes was similar across deprivation quintiles.<\/jats:p><jats:p>Our findings support the recruitment of participants from all socioeconomic strata to allow assessment of data generalisability to routine clinical practice.<\/jats:p>","DOI":"10.1183\/23120541.00193-2019","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T13:55:12Z","timestamp":1584366912000},"page":"00193-2019","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of socioeconomic status on participation and outcomes in the Salford Lung Studies"],"prefix":"10.1183","volume":"6","author":[{"given":"Rupert","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-9194","authenticated-orcid":false,"given":"Dominy","family":"Browning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawar","family":"Diar Bakerly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6355-6362","authenticated-orcid":false,"given":"J\u00f8rgen","family":"Vestbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Leather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Svedsater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Collier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"key":"2024101707453822000_6.1.00193-2019.1","doi-asserted-by":"publisher","DOI":"10.3109\/15412555.2011.648030"},{"key":"2024101707453822000_6.1.00193-2019.2","unstructured":"British Lung Foundation. Asthma Statistics. https:\/\/statistics.blf.org.uk\/asthma Date last accessed: July 22, 2019. Date last updated: 2020."},{"key":"2024101707453822000_6.1.00193-2019.3","unstructured":"British Lung Foundation. Chronic Obstructive Pulmonary Disease (COPD) Statistics. https:\/\/statistics.blf.org.uk\/copd Date last accessed: July 22, 2019. Date last updated: 2020."},{"key":"2024101707453822000_6.1.00193-2019.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090145"},{"key":"2024101707453822000_6.1.00193-2019.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2004.03.026"},{"key":"2024101707453822000_6.1.00193-2019.6","doi-asserted-by":"publisher","DOI":"10.1159\/000355082"},{"key":"2024101707453822000_6.1.00193-2019.7","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa1608033","article-title":"Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice","volume":"375","author":"Vestbo","year":"2016","journal-title":"N Engl J Med"},{"key":"2024101707453822000_6.1.00193-2019.8","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(17)32397-8","article-title":"Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial","volume":"390","author":"Woodcock","year":"2017","journal-title":"Lancet"},{"key":"2024101707453822000_6.1.00193-2019.9","unstructured":"Department for Communities and Local Government. The English Indices of Deprivation 2010. www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/6871\/1871208.pdf Date last accessed: July 22, 2019. Date last updated: March 2011."},{"key":"2024101707453822000_6.1.00193-2019.10","unstructured":"GlaxoSmithKline. GSK Clinical Study Register. Study HZA115150 Clinical Study Report. http:\/\/s3.amazonaws.com\/ctr-gsk-7381\/115150\/6445927f-953c-402f-a79a-6ca22d93169c\/e1e0596f-8dc8-4212-9e04-ce2a778d0e6d\/gsk-115150-clinical-study-report-redact-v1.pdf Date last accessed: July 22, 2019. Date last updated: 29 September 2017."},{"key":"2024101707453822000_6.1.00193-2019.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.147058"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00193-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:55Z","timestamp":1740373315000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00193-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,16]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1183\/23120541.00193-2019"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00193-2019","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}